{"id":4658,"date":"2025-03-31T18:12:15","date_gmt":"2025-03-31T18:12:15","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/ribavirin-txt\/"},"modified":"2025-03-31T18:12:15","modified_gmt":"2025-03-31T18:12:15","slug":"ribavirin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/ribavirin-txt\/","title":{"rendered":"ribavirin.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nAntiviral agent:Severe respiratory syncytial virus bronchiolitisChronic Hepatitis C in combination with Interferon \u03b1 or Peginterferon \u03b1

DOSE IN NORMAL RENAL FUNCTION <\/H3>Bronchiolitis: 6 g nebulised daily for 12\u201318 hours for 3\u20137 daysHepatitis C:Rebetol:85 kg: 600 mg twice dailyCopegus: 75 kg: 600 mg twice daily \u2014

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :244.2<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :0<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 10\u201340<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :Nebulised: 647 litres; Oral: 5000 litres<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :Nebulised: 9\/\u2013; Oral: 79\/Increased

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function. Avoid oral. See \u2018Other Information\u2019
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function. Avoid oral. See \u2018Other Information\u2019
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. Avoid oral. See \u2018Other Information\u2019

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL\/min<\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antivirals: ribavirin may antagonise the effects of stavudine; increased side effects with didanosine

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>Dissolve contents of one vial in water for injection

    Route <\/H4>Nebulised, oral, IV

    Rate of Administration <\/H4>IV: over 10\u201315 minutes

    Comments<\/H4>Nebulised: further dilute to a volume of 300 mL

    OTHER INFORMATION <\/H4>Oral: Administer ribavirin with interferon \u03b1 3 MIU 3 times a week or peginterferon \u03b1 1.5 mcg\/kg\/week\n
  • Contraindicated by the company due to reduced clearance leading to increased side effects. Ribavirin is metabolised by reversible phosphorylation and a degradative pathway involving deribosylation and amide hydrolysis to produce renally excreted active metabolites
    There are two studies using ribavirin (200\u2013400 mg a day) in combination with interferon in haemodialysis and peritoneal dialysis patients. Anaemia was one of the main problems, resulting in either increased doses of erythropoietin or discontinuation of ribavirin therapy. Most patients were stabilised on a dose of 200 mg daily or 200 mg 3 times a week.
    A dose of 200 mg daily gave troughs comparable to those in patients with normal renal function taking 1200 mg daily. (
    \n patients with \u2014end-stage renal disease <\/p>\n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Antiviral agent:Severe respiratory syncytial virus bronchiolitisChronic Hepatitis C<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4658","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4658","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4658"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4658\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4658"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4658"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4658"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}